http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5990317-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d75b123e25d2349569068e97ae3903f5 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D233-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D233-64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-415 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D233-64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D233-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D233-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D233-54 |
| filingDate | 1996-05-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 1999-11-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1da93819a3e83c735ebd5bc429b117cd http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3d7ca69a6cc77f028cb615cce18a71eb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2c631432a97684c573af10793642362a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3cc8e5db13c490a2c44fc7ba45f41cc2 |
| publicationDate | 1999-11-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-5990317-A |
| titleOfInvention | 2-(1H-4(5)-imidazoyl) cyclopropyl compounds |
| abstract | PCT No. PCT/US96/07833 Sec. 371 Date Feb. 6, 1998 Sec. 102(e) Date Feb. 6, 1998 PCT Filed May 29, 1996 PCT Pub. No. WO96/38141 PCT Pub. Date Dec. 5, 1996The present invention provides compounds having H3 histamine receptor antagonist activity of formula (1.0) wherein R2 is a hydrogen or a methyl or ethyl group; R3 is a hydrogen or a methyl or ethyl group; n is 0, 1, 2, 3, 4, 5, or 6; and R1 is selected from the group consisting of (a) C3 to C8 cycloalkyl; (b) phenyl or substituted pneyly; (c) alkyl; (d) heterocyclic; (e) decahydronaphthalene; and (f) octahydroindene; with the proviso that when X is H, A can be -CH2CH2, -COCH2-CON(CH3)-, -CH=CH-, alpha , -CH2-NH-, -CH3-N(CH3)-, -CH(OH)CH2-, -NH-CH2-, -N(CH3)-CH2-, -CH2O-, -CH2S-, and -NHCOO-; when X is NH2, HN(CH3), N(CH3)2, OH, OCH3, CH3, SH and SCH3; A can be -NHCO-, -N(CH3)-CO-, -NHCH2-, -N(CH3)-CH2-, -CH=XH-, -COCH2-, -CH2CH2-, -CH( )H)CH2-, or beta ; and when R1 and X taken together denote a 5,6 or 6,6 saturated bicyclic ring structure, X can be NH, O, or S. The pharmaceutically acceptable salts, hydrates, and individual stereoisomers of compounds of structural formula (1.0), as well as mixtures thereof, are also contemplated as falling within the scope of the present invention. The invention also provides pharmaceutical compositions comprising a pharmaceutically acceptable carrier in combination with an effective amount of a compound of said formula and a method of treating conditions in which antagonism of histamine H3 receptors may be of therapeutic importance. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2005080361-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0063296-A3 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2002042400-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8486947-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6794405-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8017646-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010137391-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8076329-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2004006120-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2003166706-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2008182876-A1 |
| priorityDate | 1995-05-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 647.